This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Reis, R. M. Articles by Ohgaki, H. Search for Related Content PubMed PubMed Citation Articles by Reis, R. M. Articles by Ohgaki, H.

(American Journal of Pathology. 2000;156:425-432.)
© 2000 American Society for Investigative Pathology

Short Communications

Genetic Profile of Gliosarcomas

Rui M. Reis^*, Dilek Könü-Lebleblicioglu, Jose Manuel Lopes, Paul Kleihues^* and Hiroko Ohgaki^*

From the International Agency for Research on Cancer,^*
Lyon, France; the Department of Neurosurgery,
University Hospital, Zurich, Switzerland; and the Institute of Pathology and Molecular Immunology,
Medical Faculty of Porto, Porto, Portugal

There are distinct genetic pathways leading to the glioblastoma, the most malignant astrocytic brain tumor. Primary (de novo) glioblastomas develop in older patients and are characterized by epidermal growth factor (EGF) receptor amplification/overexpression, p16 deletion, and PTEN mutations, whereas secondary glioblastomas that progressed from low-grade or anaplastic astrocytoma develop in younger patients and frequently contain p53 mutations. In this study, we assessed the genetic profile of gliosarcoma, a rare glioblastoma variant characterized by a biphasic tissue pattern with alternating areas displaying glial and mesenchymal differentiation. Single-strand conformation polymorphism followed by direct DNA sequencing revealed p53 mutations in five of 19 gliosarcomas (26%) and PTEN mutations in seven cases (37%). Homozygous p16 deletion was detected by differential polymerase chain reaction in seven (37%) gliosarcomas. The overall incidence of alterations in the Rb pathway (p16 deletion, CDK4 amplification, or loss of pRb immunoreactivity) was 53%, and these changes were mutually exclusive. Coamplification of CDK4 and MDM2 was detected in one gliosarcoma. None of the gliosarcomas showed amplification or overexpression of the EGF receptor. Thus gliosarcomas exhibit a genetic profile similar to that of primary (de novo) glioblastomas, except for the absence of EGFR amplification/overexpression. Identical PTEN mutations in the gliomatous and sarcomatous tumor components were found in two cases. Other biopsies contained p16 deletions, an identical p53 mutation, or coamplification of MDM2 and CDK4 in both tumor areas. This strongly supports the concept of a monoclonal origin of gliosarcomas and an evolution of the sarcomatous component due to aberrant mesenchymal differentiation in a highly malignant astrocytic neoplasm.

This article has been cited by other articles:

				S. Tejada, M. V. T. Lobo, M. Garcia-Villanueva, S. Sacristan, M. I. Perez-Morgado, M. Salinas, and M. E. Martin Eukaryotic Initiation Factors (eIF) 2{alpha} and 4E Expression, Localization, and Phosphorylation in Brain Tumors J. Histochem. Cytochem., May 1, 2009; 57(5): 503 - 512. [Abstract] [Full Text] [PDF]

				S. Fischer, W. Lee, E. Aulisi, and H. Singh Gliosarcoma With Intramedullary Spinal Metastases: A Case Report and Review of the Literature J. Clin. Oncol., February 1, 2007; 25(4): 447 - 449. [Full Text] [PDF]

				S. Patane, S. Avnet, N. Coltella, B. Costa, S. Sponza, M. Olivero, E. Vigna, L. Naldini, N. Baldini, R. Ferracini, et al. MET Overexpression Turns Human Primary Osteoblasts into Osteosarcomas. Cancer Res., May 1, 2006; 66(9): 4750 - 4757. [Abstract] [Full Text] [PDF]

				G. Stoica, H.-T. Kim, D. G. Hall, and J. R. Coates Morphology, Immunohistochemistry, and Genetic Alterations in Dog Astrocytomas Vet. Pathol., January 1, 2004; 41(1): 10 - 19. [Abstract] [Full Text] [PDF]

				C. Walker, D. G. du Plessis, K. A. Joyce, Y. Machell, J. Thomson-Hehir, S. A. Al Haddad, J. C. Broome, and P. C. Warnke Phenotype versus Genotype in Gliomas Displaying Inter- or Intratumoral Histological Heterogeneity Clin. Cancer Res., October 15, 2003; 9(13): 4841 - 4851. [Abstract] [Full Text] [PDF]

				E. S. Calhoun, J. B. Jones, R. Ashfaq, V. Adsay, S. J. Baker, V. Valentine, P. M. Hempen, W. Hilgers, C. J. Yeo, R. H. Hruban, et al. BRAF and FBXW7 (CDC4, FBW7, AGO, SEL10) Mutations in Distinct Subsets of Pancreatic Cancer: Potential Therapeutic Targets Am. J. Pathol., October 1, 2003; 163(4): 1255 - 1260. [Abstract] [Full Text] [PDF]

				C. B. Knobbe, A. Merlo, and G. Reifenberger Pten signaling in gliomas Neuro-oncol, July 1, 2002; 4(3): 196 - 211. [Abstract] [PDF]

				J. D. Potter Morphostats: A Missing Concept in Cancer Biology Cancer Epidemiol. Biomarkers Prev., March 1, 2001; 10(3): 161 - 170. [Abstract] [Full Text]